Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE: Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump has been available for the past 25 years. CIPII, with its specific pharmacodynamic properties, may be a viable treatment alternative to improve glycemic control in patients with type 1 diabetes for whom other therapies have failed. There have been few studies in which CIPII was compared with subcutaneous insulin treatment for patients with type 1 diabetes with poor glycemic control. RESEARCH DESIGN AND METHODS: In an open-label, prospective, crossover, randomized, 16-month study, the effects of CIPII and subcutaneous insulin were compared in 24 patients. The primary outcome measure was the incidence of hypoglycemia. Secondary outcome measures were A1C, and glucose profile, including time in euglycemia, as measured by continuous glucose monitoring. RESULTS: The incidence of grade 1 hypoglycemic events was 4.0 ± 2.6 per week with subcutaneous insulin compared with 3.5 ± 2.3 per week during CIPII (P = 0.13). The absolute mean difference in A1C with CIPII compared with subcutaneous treatment was −0.76% (95% CI −1.41 to −0.11) (P = 0.03). Baseline time spent in euglycemia was 45.2 ± 12.6% and increased 10.9% (4.6–17.3) with CIPII compared with subcutaneous treatment (absolute value; P = 0.003). There were no differences in the occurrence rate for severe hypoglycemic events, daily insulin use, or BMI. No pump or catheter malfunction was observed during the study. CONCLUSIONS: Although we did not observe a significant reduction in hypoglycemic events, improved glycemic control was achieved with the use of CIPII. We saw a 0.8% decrease in A1C and an 11% increase in the time spent in euglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes
Gregory, J. M., Cherrington, A. D., & Moore, D. J. (2020) · Diabetes · doi:10.2337/dbi19-0026 · Cited by 76
Evolution of Devices in Diabetes Management
Penfornis, A., Personeni, E., & Borot, S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0058 · Cited by 49
“17,27 Furthermore, a recent study conducted in patients with T1DM reported that CSII offered no benefits over insulin glargine-based MDI with regard to glycemic control and was associated with around fourfold higher costs.”
InfluentialSpaan, N., Teplova, A., Stam, G., Spaan, J., & Lucas, C. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0557-3 · Cited by 46
Metadata
- Authors
- Logtenberg, S. J., Kleefstra, N., Houweling, S. T., Groenier, K. H., Gans, R. O., van Ballegooie, E., & Bilo, H. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-05-08
- Volume
- 32
- Issue
- 8
- Pages
- 1372-1377
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2037423817
- Cited by
- 68
- References
- 0
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc08-2340
- The paper
- Logtenberg, S. J., Kleefstra, N., Houweling, S. T., Groenier, K. H., Gans, R. O., van Ballegooie, E., & Bilo, H. J. (2009). Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc08-2340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.